Skip to main content

Leukocyte Telomere Length and Response to Antiangiogenic Therapy in Patients with Neovascular Age-Related Macular Degeneration

Abstract

Age-related macular degeneration (AMD) is becoming the leading cause of vision loss in people over 60 yr of age. The neovascular form of AMD (nAMD) is characterized by choroidal neovascularization (CNV), the main trigger of which is vascular endothelial growth factor (VEGF), the inhibition of which is the current standard of treatment. Significant variability of response to anti-VEGF therapy determines the relevance of the search for biological markers—prognostic criteria of treatment response. We analyzed the response of 110 nAMD patients to anti-VEGF therapy depending on the functional and anatomical parameters of the retina (according to optical coherence tomography, OCT) and leukocyte telomere length (LTL, was assessed by quantitative PCR). Positive dynamics of best corrected visual acuity (BCVA) was observed in 100% of eyes. The central retinal thickness (CRT) decreased after the 3rd injection to 265 [234–306] µm, by the end of the observation period—to 211 [190–262] µm. The retention of activity of the subretinal neovascular membrane (SNM) at the end of the observation period correlated with lower values of the initial BCVA and high values of the initial CRT. An association of LTL with response to treatment was revealed: in patients with longer LTL the active form of SNM was more often switched to inactive after three injections, while with shorter LTL, the activity of SNM was more often preserved, which determined the need for more intravitreal injections.

This is a preview of subscription content, access via your institution.

Fig. 1.
Fig. 2.

REFERENCES

  1. Banevicius, M., Gedvilaite, G., Vilkeviciute, A., et al., Association of relative leukocyte telomere length and genetic variants in telomere-related genes (TERT, TERT-CLPTM1, TRF1, TNKS2, TRF2) with atrophic age-related macular degeneration, Ophthalmol. Genet., 2021, vol. 42, no. 2, pp. 189–194. https://doi.org/10.1080/13816810.2021.1881976

    CAS  Article  Google Scholar 

  2. Berezutsky, M.A., Durnova, N.A., and Vlasova, I.A., Experimental and clinical studies of mechanisms of the antiaging effects of chemical compounds in Astragalus membranaceus, Adv. Gerontol., 2020, vol. 10, no. 2, pp. 142–149. https://doi.org/10.1134/S2079057020020046

    Article  Google Scholar 

  3. Bernadotte, A., Mikhelson, V.M., and Spivak, I.M., Markers of cellular senescence. Telomere shortening as a marker of cellular senescence, Aging (Albany, New York), 2016. https://doi.org/10.18632/aging.100871

  4. Bhisitkul, R., Mendes, T., Rofagha, S., et al., Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study, Amer. J. Ophthalmol., 2015, vol. 159, no. 5, pp. 915–924. https://doi.org/10.1016/j.ajo.2015.01.032

    Article  Google Scholar 

  5. Cawthon, R.M., Telomere measurement by quantitative PCR, Nucleic Acids Res., 2002, vol. 30, no. 10. e47. https://doi.org/10.1093/nar/30.10.e47

  6. Coscas, F., Cabral, D., Pereira, T., et al., Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission, PLoS One, 2018, vol. 13, no. 10. e0205513.

  7. De Punder, K., Heim, C., Wadhwa, P.D., and Entringer, S., Stress and immunosenescence: the role of telomerase, Psychoneuroendocrinology, 2019, vol. 101, pp. 87–100. https://doi.org/10.1016/j.psyneuen.2018.10.019

    CAS  Article  Google Scholar 

  8. Demanelis, K., Jasmine, F., Chen, L.S., et al., Determinants of telomere length across human tissues, Science, 2020, vol. 369, no. 6509. eaaz6876. https://doi.org/10.1126/science.aaz6876

  9. Dow, C.T. and Harley, C.B., Evaluation of an oral telomerase activator for early age-related macular degeneration—a pilot study, Clin. Ophthalmol., 2016, vol. 10, pp. 243–249. https://doi.org/10.2147/OPTH.S100042

    CAS  Article  Google Scholar 

  10. Ebner, C., Wernigg, C., Schütze, C., et al., Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration, Wien Klin. Wochenschr., 2021, vol. 133, pp. 123–130. https://doi.org/10.1007/s00508-020-01718-6

    CAS  Article  Google Scholar 

  11. Fayzieva, U.S., Maksudova, Z.R., Siddikov, Z.U., et al., Oct-angiography in the efficiency assessment of the anti-angiogenic therapy of exudative form of age-related macular degeneration, Modern Technol. Ophthalmol., 2019, vol. 1, pp. 305–309. https://doi.org/10.25276/2312-4911-2019-1-305-309

    Article  Google Scholar 

  12. Framme, C., Eter, N., Hamacher, T., et al., Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS, Ophthalmol. Retina, 2018, vol. 2, no. 6, pp. 539–549. https://doi.org/10.1016/j.oret.2017.09.017

    Article  Google Scholar 

  13. Fursova, A.Z., Derbeneva, A.S., Vasilyeva, M.A., et al., Different types localisation of retinal fluid as prognostic biomarkers in the choice of anti-VEGF therapy for age-related macular degeneration, Vestn. Oftalmol., 2020, vol. 136, no. 2, pp. 227–234. https://doi.org/10.17116/oftalma2020136062227

    Article  Google Scholar 

  14. Fursova, A.Z., Zabanova, V.E., Gamza, Y.A., et al., Ophthalmic safety profile of antiangiogenic therapy, Vestn. Oftalmol., 2021, vol. 137, no. 2, pp. 114–122. https://doi.org/10.17116/oftalma2021137021114

    Article  Google Scholar 

  15. Holz, F.G., Tadayoni, R., Beatty, S., et al., Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration, Brit. J. Ophthalmol., 2015, vol. 99, pp. 220–226. https://doi.org/10.1136/bjophthalmol-2014-305327

    Article  Google Scholar 

  16. Immonen, I., Seitsonen, S., Saionmaa, O., and Fyhrquist, F., Leucocyte telomere length in age-related macular degeneration, Acta Ophthalmol., 2013, vol. 91, no. 5, pp. 453–456. https://doi.org/10.1111/j.1755-3768.2012.02427.x

    CAS  Article  Google Scholar 

  17. Lambert, N.G., ElShelmani, H., Singh, M.K., et al., Risk factors and biomarkers of age-related macular degeneration, Progr. Retinal Eye Res., 2016, vol. 54, pp. 64–102. https://doi.org/10.1016/j.preteyeres.2016.04.003

    CAS  Article  Google Scholar 

  18. Maximov, V.N., Malyutina, S.K., Orlov, P.S., et al., Leukocyte telomere length as an aging marker and risk factor for human age-related diseases, Adv. Gerontol., 2017, vol. 7, pp. 101–106. https://doi.org/10.1134/S2079057017020102

    Article  Google Scholar 

  19. Neroev, V.V., Astakhov, Y.S., Korotkih, S.A., et al., Protocol of intravitreal drug delivery. Consensus of the Expert Council of retina and optic nerve diseases of the All-Russian Public Organization “Association of Ophthalmologists,” Vestn. Oftalmol., 2020, vol. 136, pp. 251–263. https://doi.org/10.17116/oftalma2020136062251

    CAS  Article  Google Scholar 

  20. Peden, M., Suñer, I., Hammer, M., and Grizzard, W., Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration, Ophthalmology, 2015, vol. 122, no. 4, pp. 803–808. https://doi.org/10.1016/j.ophtha.2014.11.018

    Article  Google Scholar 

  21. Stefler, D., Malyutina, S., Maximov, V., et al., Leukocyte telomere length and risk of coronary heart disease and stroke mortality: prospective evidence from a Russian cohort, Sci. Rep., 2018, vol. 8, p. 16627. https://doi.org/10.1038/s41598-018-35122-y

    Article  Google Scholar 

  22. Telegina, D.V., Kozhevnikova, O.S., and Kolosova, N.G., Molecular mechanisms of cell death in retina during development of age-related macular degeneration, Adv. Gerontol., 2017, vol. 7, pp. 17–24. https://doi.org/10.1134/S2079057017010155

    Article  Google Scholar 

  23. Waldstein, S.M., Simander, C., Staurenghi, G., et al., Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the view trials, Ophthalmology, 2016, vol. 123, pp. 1521–1529. https://doi.org/10.1016/j.ophtha.2016.03.037

    Article  Google Scholar 

  24. Wang, J., Feng, Y., Han, P., et al., Photosensitization of A2E triggers telomere dysfunction and accelerates retinal pigment epithelium senescence, Cell Death Dis., 2018, vol. 9, no. 2, p. 178. https://doi.org/10.1038/s41419-017-0200-7

    CAS  Article  Google Scholar 

  25. Weng, X., Zhang, H., Kan, M., et al., Leukocyte telomere length is associated with advanced age-related macular degeneration in the Han Chinese population, Exp. Gerontol., 2015, no. 69, pp. 36–40. https://doi.org/10.1016/j.exger.2015.06.004

  26. Wong, W., Su, X., Li, X., et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Global Health, 2014, vol. 2, no. 2, рр. e106–е116. https://doi.org/10.1016/S2214-109X(13)70145-1

  27. Wykoff, C.C., Clark, W.L., Nielsen, J.S., et al., Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration, J. Manage. Care Spec. Pharm., 2018, vol. 24, pp. 3–15. https://doi.org/10.18553/jmcp.2018.24.2-a.s3

    Article  Google Scholar 

Download references

Funding

This work was supported by a grant from the Russian Science Foundation no. 21-15-00047.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to O. S. Kozhevnikova.

Ethics declarations

Conflict of interest. The authors declare that they have no conflicts of interest.

Statement of compliance with standards of research involving humans as subjects. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Russian National Standard for Good Clinical Practice. Informed consent was obtained from all patients.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fursova, A.Z., Derbeneva, A.S., Tarasov, M.S. et al. Leukocyte Telomere Length and Response to Antiangiogenic Therapy in Patients with Neovascular Age-Related Macular Degeneration. Adv Gerontol 12, 135–142 (2022). https://doi.org/10.1134/S2079057022020072

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S2079057022020072

Keywords:

  • age-related macular degeneration
  • neovascularization
  • anti-VEGF therapy
  • leukocyte telomere length